Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randamized Prospective Study
Phase 2
Recruiting
- Conditions
- Hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000012484
- Lead Sponsor
- Hanshin Association of Molecular Targeted Therapy for HCC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1) Vascular invasion 2) Obstruction in the hepatic artery 3) Sever complication such as belows a.cardiac failure b.renal failure c.active infection (except for viral hepatitis) d.active bleeing in gastrointestinal tract e.active other cancer f.Hepatic encepharopathy or severe Mental disorder 4)High fever more than 38 degrees C 5)Not only pregnant or lacting women, but women with suspected pregnancy 6)Inappropriate patients for this study judged by physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression free survival
- Secondary Outcome Measures
Name Time Method overall survival, response rate, rate of overall recurrence, rate of local recurrence, post treatment response rate of Sorafenib, drop out rate of the treatment, relative dose intensity, safety, tumor markers